Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 806 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SARS Pneumonia Clear all
Not listed No phase listed Observational Accepts healthy volunteers

The Covid-19 HEalth caRe wOrkErS (HEROES) Study

NCT04352634
View directory record Official record
Conditions
Covid-19, Mental Health Disorder, Stress Disorder, Anxiety, Depression, SARS-CoV-2
Interventions
Exposure to the SARS-CoV-2 and its consequences
Other
Lead sponsor
University of Chile
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 7, 2026, 4:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Clinical Performance Evaluation of the CareSuperb™ COVID-19 Antigen Home Test

NCT05771714
View directory record Official record
Conditions
COVID-19
Interventions
CareSuperb COVID-19 Antigen Home Test Kit
Device
Lead sponsor
AccessBio, Inc.
Other
Eligibility
2 Years and older
Enrollment
786 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

NCT05119855
View directory record Official record
Conditions
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions
9vHPV Vaccine, mRNA-1273 Vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 11 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask

NCT04979858
View directory record Official record
Conditions
Covid19, SARS-CoV2 Infection
Interventions
Focal Mask
Device
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

NCT04540406
View directory record Official record
Conditions
Suspected or Confirmed COVID-19
Interventions
NBT-NM108, Usual Care Only
Drug · Other
Lead sponsor
Notitia Biotechnologies Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

NCT05463068
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
NVX-Cov2373
Drug
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
30
States / cities
Long Beach, California • Sacramento, California • DeLand, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

NCT04388527
View directory record Official record
Conditions
Covid-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 7, 2026, 4:37 PM EDT
Terminated Phase 3 Interventional Results available

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397
View directory record Official record
Conditions
Kidney Transplant Recipient
Interventions
Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
Biological · Other
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 7, 2026, 4:37 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

NCT05040659
View directory record Official record
Conditions
Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza, Healthy, PASC Post Acute Sequelae of COVID 19
Interventions
AROMHA Longitudinal Smell Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 7, 2026, 4:37 PM EDT
Completed No phase listed Observational

SARS-CoV-2 IgG and IgM Serologic Assays

NCT04562246
View directory record Official record
Conditions
Covid19
Interventions
Serologic assays for antibodies to SARS-CoV-2
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 7, 2026, 4:37 PM EDT
Completed No phase listed Observational

Role of OMT in the Management of the Persistent Post-COVID-19 Symptoms

NCT06016543
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
osteopathic manipulative treatment (OMT)
Procedure
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 1Phase 2 Interventional

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

NCT04494386
View directory record Official record
Conditions
Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions
Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control)
Biological · Other
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Miami, Florida • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 7, 2026, 4:37 PM EDT
Withdrawn Phase 2 Interventional

A Study of Combination Therapies to Treat COVID-19 Infection

NCT04459702
View directory record Official record
Conditions
COVID, COVID-19, Corona Virus Infection, Coronavirus Infection, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, Coronavirus-19, SARS-CoV 2, SARS Pneumonia
Interventions
hydroxychloroquine, Azithromycin, Ritonavir, Lopinavir
Drug
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of LAM-002A for the Prevention of Progression of COVID-19

NCT04446377
View directory record Official record
Conditions
COVID-19 Disease
Interventions
Apilimod Dimesylate Capsule, Placebo
Drug · Other
Lead sponsor
OrphAI Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 7, 2026, 4:37 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

NCT07703475
View directory record Official record
Conditions
COVID -19
Interventions
RVX-sCPD9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 3 Interventional

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

NCT04629703
View directory record Official record
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Interventions
Fostamatinib, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 7, 2026, 4:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

NCT04778059
View directory record Official record
Conditions
2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection, Respiratory Distress Syndrome, Adult, Adult Respiratory Distress Syndrome
Interventions
USB002, Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 7, 2026, 4:37 PM EDT
Terminated Phase 1 Interventional

Anti-SARS Cov-2 T Cell Infusions for COVID 19

NCT04401410
View directory record Official record
Conditions
SARS-CoV 2, Viral Infection, COVID 19
Interventions
Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs)
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

NCT04939428
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
59
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 7, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

Sargramostim Use in COVID-19 to Recover Patient Health

NCT04707664
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Sargramostim, Placebo
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 7, 2026, 4:37 PM EDT
Not listed No phase listed Observational

FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol

NCT05928507
View directory record Official record
Conditions
Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
Interventions
Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
Diagnostic Test
Lead sponsor
Baebies, Inc.
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 7, 2026, 4:37 PM EDT